We are using cookies to implement functions like login, shopping cart or language selection for this website. Furthermore we use Google Analytics to create anonymized statistical reports of the usage which creates Cookies too. You will find more information in our privacy policy.
OK, I agree I do not want Google Analytics-Cookies
Oral Health and Preventive Dentistry



Forgotten password?


Dear readers,

our online journals are moving. The new (and old) issues of all journals can be found at
In most cases you can log in there directly with your e-mail address and your current password. Otherwise we ask you to register again. Thank you very much.

Your Quintessence Publishing House
Oral Health Prev Dent 13 (2015), No. 5     2. Nov. 2015
Oral Health Prev Dent 13 (2015), No. 5  (02.11.2015)

Page 385-393, doi:10.3290/j.ohpd.a34055, PubMed:25884045

New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws
Ramírez, Lucía / López-Pintor, Rosa María / Casañas, Elisabeth / Arriba, Lorenzo de / Hernández, Gonzalo
Purpose: The aim of this paper was to review the current literature associating the non-bisphosphonate cancer-treatment drugs Denosumab, Bevacizumab and Sunitinib (used with or without bisphosphonate [BP]) with the presence of osteonecrosis of the jaws (ONJ) in patients.
Materials and Methods: A literature review was conducted using the keywords osteonecrosis of the jaws, oral biphosphosnates, Denosumab, Bevacizumab and Sunitinib. Articles were obtained that reported cases of ONJ associated with the use of Denosumab, Bevacizumab and Sunitinib.
Results: The literature shows that Denosumab can cause ONJ associated with triggers such as microtraumas or dental extractions. The combination of the drug along with zoledronic acid may have a synergistic effect. Bevacizumab may cause ONJ; however, there is much controversy regarding its synergistic action when used with BP. Sunitinib causes ONJ, and together with BP could increase the risk of developing lesions.
Conclusion: Denosumab, Sunitinib or Bevacizumab are causal agents in the development of ONJ. The combination of any of these along with BPs could increase the risk of developing ONJ over that posed by BP treatment alone.

Keywords: Bevacizumab, Denosumab, osteonecrosis, Sunitinib
fulltext (no access granted) Endnote-Export